Company news
Resverlogix Corp. (TSX:RVX) news
Resverlogix Corp. news releases on 6ix. Latest, Apr 23, 2012: Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
Press releases — page 4
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
April 23, 2012
Resverlogix Conference Call & Webcast to Announce Platform Mechanism of Action
April 19, 2012
Resverlogix to Present at The 14th Annual BIO CEO & Investor Conference
February 8, 2012
Resverlogix Enters Into Equity Distribution Agreement
January 19, 2012
Resverlogix Closes Equity Offering
November 29, 2011
Resverlogix Announces Full Enrollment of SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
November 28, 2011
Resverlogix Announces $17.5 million Equity Offering
November 23, 2011
Resverlogix Announces the Issuing of Patent Covering RVX-208
November 15, 2011
Resverlogix Commences Dosing in ASSURE a Phase 2b IVUS Clinical Trial Targeting High-Risk Cardiovascular Disease Patients
November 2, 2011
Resverlogix Expands Phase 2b Program with the Commencement of Dosing in SUSTAIN
September 27, 2011
Resverlogix Activates Study Sites in ASSURE Phase 2b IVUS Trial for Atherosclerotic Plaque Regression
September 26, 2011
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011
September 1, 2011
Resverlogix Presents New Findings on RVX-208 at European Atherosclerosis Society
June 27, 2011
Resverlogix Announces New Data on Autoimmune Program featured at World Congress of Inflammation
June 27, 2011
Resverlogix Announces Dr. H. Bryan Brewer Joins Clinical Steering Committee
June 23, 2011
Resverlogix Launches Phase IIb ASSURE Trial for RVX-208 Cholesterol Transport Drug, Safety Data Completed and Filed
June 13, 2011
Investment Industry Regulatory Organization of Canada - Trade Resumption - Resverlogix Corp. - RVX
June 3, 2011
Resverlogix to Raise $12.6 Million
June 3, 2011
Investment Industry Regulatory Organization of Canada - Trading Halt - Resverlogix Corp. - RVX
June 3, 2011
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease
January 25, 2011
Resverlogix Appoints Dr. Eldon R. Smith to Board of Directors
December 13, 2010
Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
November 29, 2010
Resverlogix Notice of Conference Call & Webcast to Provide a Market Update
November 25, 2010
Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
November 17, 2010
Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
November 15, 2010
Resverlogix Appoints Kenneth J. Zuerblis to Board of Directors
September 30, 2010
Standard & Poor's Announces the Annual Review of the S&P/TSX SmallCap Index
September 10, 2010
Resverlogix's Phase 2 ASSURE Trial Amended
September 10, 2010
Resverlogix Surpasses $1 Billion Trading Milestone
August 23, 2010
Resverlogix Scientific Data Presented at EAS Congress
June 22, 2010
Resverlogix Announces CDN $10 Million Equity Offering
June 16, 2010
Resverlogix Settles Draw Down on Standby Equity Distribution Agreement
June 11, 2010
Resverlogix Publishes Data Confirming RVX-208's Impact on Reverse Cholesterol Transport
June 8, 2010
Resverlogix Confirms CDN $9.2 Million Offering
June 3, 2010
Resverlogix Announces Financing
June 2, 2010
Resverlogix Announces Intention to Draw Down $1 Million on Standby Equity Distribution Agreement
May 26, 2010
Resverlogix Completes Dosing for ASSERT Trial
May 12, 2010
Resverlogix Notice of Conference Call & Webcast for Year End Update
May 10, 2010
Resverlogix Scientific Data Presented at ATVB Conference
April 9, 2010
Resverlogix Activates Standby Equity Distribution Agreement
March 29, 2010
GuestLogix Inc. and Redknee Solutions Inc. Under Current Evaluation
March 9, 2010
Resverlogix Market Update
March 5, 2010
Resverlogix Activates First Site for ASSURE 1 Clinical Trial
February 25, 2010
Resverlogix Completes Patient Recruitment for ASSERT Trial
February 8, 2010
Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of Directors
February 1, 2010
Resverlogix Announces the Closing of an Additional $8 Million Financing
January 28, 2010
Resverlogix Presenting at Biotech Showcase
January 11, 2010
Resverlogix Confirms the Completion of Full Debenture Repurchase
January 7, 2010
Resverlogix Announces a $5 Million Financing
December 23, 2009
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
December 22, 2009